tiprankstipranks
Advertisement
Advertisement

IT:1BMRN Stock Latest News

BioMarin Shareholders Approve 2026 Governance and Equity Plan
Company AnnouncementsBioMarin Shareholders Approve 2026 Governance and Equity Plan
4d ago
8K
BMRN
Jason Gerberry Maintains Buy on BioMarin, Reiterates $80 Price Target Despite Voxzogo Patent Uncertainty
PremiumRatings
Jason Gerberry Maintains Buy on BioMarin, Reiterates $80 Price Target Despite Voxzogo Patent Uncertainty
8d ago
BMRN
BioMarin price target lowered to $111 from $116 at Canaccord
PremiumThe Fly
BioMarin price target lowered to $111 from $116 at Canaccord
17d ago
BMRN
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
18d ago
BMRN
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
PremiumThe Fly
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
19d ago
BMRN
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
PremiumThe FlyStubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
20d ago
AMT
BAP
BioMarin price target lowered to $80 from $85 at BofA
Premium
The Fly
BioMarin price target lowered to $80 from $85 at BofA
20d ago
BMRN
BioMarin initiated with a Buy at Citi
Premium
The Fly
BioMarin initiated with a Buy at Citi
21d ago
BMRN
BioMarin price target lowered to $62 from $64 at Leerink
PremiumThe Fly
BioMarin price target lowered to $62 from $64 at Leerink
21d ago
BMRN
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
PremiumThe Fly
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
21d ago
BMRN
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
PremiumThe Fly
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
21d ago
BMRN
Dell downgraded, Uber upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Dell downgraded, Uber upgraded: Wall Street’s top analyst calls
28d ago
CG
FTV
BioMarin reinstated with a Neutral at Goldman Sachs
PremiumThe FlyBioMarin reinstated with a Neutral at Goldman Sachs
28d ago
BMRN
BioMarin price target raised to $116 from $104 at Canaccord
Premium
The Fly
BioMarin price target raised to $116 from $104 at Canaccord
1M ago
BMRN
BioMarin price target lowered to $119 from $120 at Morgan Stanley
Premium
The Fly
BioMarin price target lowered to $119 from $120 at Morgan Stanley
1M ago
BMRN
BioMarin price target raised to $120 from $110 at Evercore ISI
PremiumThe Fly
BioMarin price target raised to $120 from $110 at Evercore ISI
1M ago
BMRN
BioMarin price target lowered to $82 from $94 at Bernstein
PremiumThe Fly
BioMarin price target lowered to $82 from $94 at Bernstein
1M ago
BMRN
BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged
PremiumRatings
BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged
1M ago
BMRN
BioMarin Buy Rating Reiterated on Amicus Acquisition Synergies and Long-Term Upside; $120 Price Target Unchanged
PremiumRatings
BioMarin Buy Rating Reiterated on Amicus Acquisition Synergies and Long-Term Upside; $120 Price Target Unchanged
1M ago
BMRN
BioMarin Boosts 2026 Outlook After Amicus Deal
PremiumCompany AnnouncementsBioMarin Boosts 2026 Outlook After Amicus Deal
1M ago
BMRN
BioMarin lowers FY26 non-GAAP EPS view to $4.85-$5.05 from $4.95-$5.15
Premium
The Fly
BioMarin lowers FY26 non-GAAP EPS view to $4.85-$5.05 from $4.95-$5.15
1M ago
BMRN
BioMarin reports Q1 non-GAAP EPS 76c, consensus 91c
Premium
The Fly
BioMarin reports Q1 non-GAAP EPS 76c, consensus 91c
1M ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >